Preferred Label : obiltoxaximab;

UNII : 29Z5DNL48C;

Details


Main resources

You can consult :


https://www.ema.europa.eu/en/medicines/human/EPAR/obiltoxaximab-sfl
2020
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
obiltoxaximab
obiltoxaximab
obiltoxaximab
anthrax
orphan drug production
drug therapy, combination
inhalation anthrax
bacillus anthracis
infusions, intravenous
anthrax protective antigen
product surveillance, postmarketing
Post-Exposure prophylaxis
adult
child
aged
inhalation anthrax
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
anthrax toxin
antigens, bacterial
bacterial toxins
antibodies, monoclonal
antitoxins
antibodies, monoclonal
antitoxins
respiratory tract infections
anthrax
respiratory tract infections

---
Nous contacter.
02/05/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.